I think, this is the best way of running the SICM programs.

Mock-up?

Typically "mock-up", like "wireframe", refers to a model of the user interface appearance, perhaps made with Figma or Photoshop, but I think noosphr is talking about a prototype of the functionality.

Even MIT Scheme was used with SICP, the Scheme implementation in the book is different from MIT Scheme.

MIT Scheme was for a long period one of the leading Scheme implementations. It lacks support for Apple Silicon, so it is not as popular now, as it once was.

https://www.gnu.org/software/mit-scheme/

Yes. In Apple the memory can be writable XOR executable. MIT scheme needs to write on pages that will execute, so it will trigger the MMU..

Install chicken scheme. Then:

       sudo chicken-install srfi-203

       sudo chicken-install srfi-216

At ~/.csirc put:

    (import scheme)
    (import (srfi 203))
    (import (srfi 216))

Now you can do nearly all the execises.

The stream is now live.

Livestream available.

Node.

The identifier `->` is already used for type annotations.

When a large force is applied unintentionally to a finger we have the problem. With a dull knife you need to apply a larger force than with a sharp knife. [The video illustrates this with breaking the skin of the tomato.] For a normal cut this is not a problem.

But - if the knife slips and a large force is applied at the same time - then you will get a large cut.

If the knife slips and a small force is applied, you will get a smaller cut.

If the probability of slipping is the same for sharp and dull knifes, then due to the forces applied, the cuts you get with a sharp knife are less dangerous.

The US list prices are, well, a complicated matter. For non-US readers, it is important to note that 80% of the customers (who has insurance) don't pay the list price, but rather an much more reasonable over-the-counter price.

Due to the system of insurance companies and PBMs in the US the list price is often high.

When PBMs a are negotiating with the pharmaceutical companies, they have an incentive to keep a high list price. Let's say the PBMs and a pharmaceutical company negotiates for the price of a drug X.

If the pharmaceutical company lowers the price of the drug X, and there are other comparable drugs from other companies on the market, then there is a risk that the PBM simply drops the drug X from their lists. Instead, they make a better deal (for them) on drug Y.

For the company producing X, being omitted from the insurance companies lists, is bad business.

As an outsider, it is difficult to understand that the US keeps the private insurance layer and the PBMS.

Now - the insurance companies also don't pay list prices. They get a rebate. But they - and here my memory fails me - the get some money from ... the government based on the list price.

Look at the congress hearings on the high medicine prices on YouTube.

Similar idea: https://www.youtube.com/watch?v=ueGC3xVcDlc William Bowman: First class Prompt Engineering with llm lang! (This is a bad idea.) (RacketCon)